Spero Therapeutics reports Q4 EPS (38c), consensus (31c)

Reports Q4 revenue $15.04M, consensus $6.2M. “Spero is focused on the execution of the tebipenem HBr clinical program, including preparing for the pre-specified interim analysis next quarter,” said Esther Rajavelu, Interim President and Chief Executive Officer. “We believe that, if approved, tebipenem HBr could address a critical unmet need for an oral carbapenem in the treatment of patients with complicated urinary tract infections. Tebipenem HBr has the potential to shorten hospital stays, improve patient outcomes, and alleviate pressure on healthcare resources.” Rajavelu added: “As previously announced, we are reviewing the comprehensive data we’ve gathered for SPR720 after suspending development of the oral program for NTM-PD. There remains a high unmet need for new, approved therapies for this difficult to treat disease, and a complete data analysis would enable us to make an informed decision on the program. Further, we have decided to discontinue our SPR206 program, following a pipeline review and reprioritization. We are grateful to our partners and the government agencies who helped finance this program and to the Spero team members who have worked diligently on its progression into a Phase 2 ready asset.”